ISSN 2415-3060 (print), ISSN 2522-4972 (online)
JMBS
  • 11 of 59
Up
JMBS 2016, 1(1): 55–57
https://doi.org/10.26693/jmbs01.01.055
Medicine

Treatment of Good-Quality Processes of the Uterus at Women of Reproductive Age

Dybenko D.E., Kovalchuk K.V., Lastovetskaya L.D., Kurochka V.V., Golopikha L.I.
Abstract

The influence of hormonal therapy a-GnRH and LNG-IUD on clinical course and homeostasis indexes in women with adenomyosis, endometrial hyperplasia and combined uterus pathology was learned in dynamics. New pathogenesis units in benign uterus pathology by means of immune system dysfunction that was defined in decreased levels of cytotoxic index of NK-cells were revealed. Complex hormonal therapy in reproductive-aged women with combined benign uterus pathology was developed and estimation of influence on oncomarker indexes, immune status, steroid hormones and hematological indexes in observation dynamics was conducted. In recent years, the new approaches to conservative and surgical treatments for benign uterine pathology, but there is no single algorithm that determines the strategy and tactics of such patients. In the early stages of the disease possible a differentiated approach to the treatment of women with adenomyosis and endometrial hyperplasia, which have not implemented their reproductive function. Development of modern medicines has expanded the possibilities of conservative treatment of benign uterine pathology. The greatest practical value of the entire arsenal of drugs currently represents hormone therapy. The aim of our research is to improve with conservative treatment of adenomyosis endometrial hyperplasia in women of reproductive age by implementing a comprehensive phased hormone therapy. Materials and methods of our study: Stage - assess the impact of hormone therapy combined 135 women with benign disorders of the uterus (adenomyosis hyperplasia of the endometrium). And the group was 69 women; II group - 66 women. Stage - assess the effectiveness of combined complex treatment of benign uterine pathology in 35 women of reproductive age (group III) in our proposed scheme. Menstrual disorders by type hyperpolymenorrhoea prior hormone was detected in 92.6 % of surveyed women. The volume of menstrual blood loss was determined using maps and menstrual blood loss was in the first and second groups of women - 183 points, in the third group - 206 points, twice exceeded performance standards.We evaluated the pain in the background of hormone therapy in women with benign uterine pathology. In all the surveyed groups 3 and 6 months of intensive observation marked decrease in pain index.The evaluation of the impact of hormone therapy on the level of steroid hormones. Indicators of estradiol (E2) was significantly decreased in 3 months - in 1.5 times to 6 - to 75.45 % of the initial data, 12 months E2 level was 0,35 ± 0,04 nmol / l.By 6 months of observation there was a significant reduction of its (0,1 ± 0,01 nmol / L) for 12 months, recorded increase of the indicator to normal. Normal progesterone levels at 3 months of hormone therapy in all three groups and were not significantly changed during the follow up period.In the second group after 6 months held hysteroscopy with endometrial biopsy: all women - atrophy of the endometrium.We have developed a comprehensive phased hormone therapy for women of reproductive age with combined benign pathology of the uterus (adenomyosis hyperplasia of the endometrium) normalizes indices of tumor markers, and humoral immune status. This treatment significantly improves the surveyed women hematology, ultrasound, endoscopic and morphological indicators in the dynamics of observation compared to monotherapy.

Keywords: complex hormone therapy, benign uterus pathology. LNG-IUD, a-GnRH

Full text: PDF (Ukr) 71.40K

References
  1. Benyuk VO, Golota VYa, Dindar OA, Usevich IA. Rol agonistiv GNRG v likuvanni endometriozu. Nauk.-prakt. konf. «Problemyi dostizheniya i perspektivyi razvitiya mediko-biologicheskih nauk». Trudyi Kryimskogo meduniversiteta. 2006;142:237.
  2. Grischenko VI, Scherbina MO, Potapova LV, LIpko OP. Zastosuvannya diferentsiyovanoyi gormonoterapiyi v likuvanni hvorih na poshireni formi genitalnogo endometriozu. Visn nauk doslidzhen. 2002; 2 (26): 8–9.
  3. Kucherenko SN. Differentsirovannaya gormonoterapiya adenomioza s uchetom osobennostey gormonalnyih narusheniy i kliniko-morfofunktsionalnyih kriteriev protsessa. Zdorov'e zhenschinyi. 2002; 3 (11): 30–6.
  4. Tatarchuk TF, Burlaka OV, KorInna KO. Medikamentozna terapiya giperproliferativnih protsesiv endometriyu. Liki ta zhittya. 2005: 100–1.
  5. Afonso JS, Sumxes Sergio S. Adenomiosis: pathohysiology, diagnosis and treatment (review). Ву Hysteroscopy at Fri. 2005; 12 (2): 1–52.
  6. Frackiewicz EJ, Zarotsky V. Diagnosis and treatment of endometriosis. Expert Opin Рharmасоthеr. 2003; 4 (1): 67–82. http://dx.doi.org/10.1517/14656566.4.1.67